Product Description
Mechanisms of Action: VEGFR2 Inhibitor,AhR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colorectal Cancer
Phase 2: Head and Neck Cancer|Gastrointestinal Stromal Tumors|Melanoma|Squamous Cell Carcinoma|Sarcoma|Mesothelioma|Uterine Cancer|Skin Cancer|Multiple Myeloma|Acute Myeloid Leukemia|Plasmacytoma|Anemia, Refractory, with Excess of Blasts|Cervical Cancer|Acute Monocytic Leukemia|Prostate Cancer|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Renal Cell Carcinoma|Myelodysplastic Syndrome|Chronic Myeloid Leukemia|Acute Myelomonocytic Leukemia|Kidney Cancer|HIV Infections|Brain Stem Cancer|Astrocytoma|Glioma|Sarcoma, Kaposi|Colorectal Cancer|Adenocarcinoma
Phase 1: Brain Stem Cancer|Oncology Solid Tumor Unspecified|Peritoneal Cancer|Fallopian Tube Cancer|Sarcoma, Kaposi|Ovarian Cancer|Head and Neck Cancer|Vascular Cancer|Prostate Cancer|Inflammatory Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SUGEN-SU5416.031 | P3 |
Completed |
Colorectal Cancer |
2007-09-01 |
|
| NCI-2012-02351 | P2 |
Completed |
Mesothelioma |
2007-02-01 |
|
| NCI-2012-02345 | P2 |
Terminated |
Colorectal Cancer |
2007-02-01 |
|
| U01CA062505 | P2 |
Completed |
Renal Cell Carcinoma|Kidney Cancer |
2007-02-01 |